Andersen Christopher R, Presseau Justin, Shea Bev, Marti Maria Luisa, McCoy Madeline, Fernie Gordon, McIntyre Lauralyn, Delaney Anthony, Chassé Michaël, Saigle Victoria, Marshall Shawn, Fergusson Dean A, Graham Ian, Brehaut Jamie, Turgeon Alexis F, Lauzier François, Tugwell Peter, Zha Xiaohui, Talbot Phil, Muscedere John, Marshall John C, Thavorn Kednapa, Griesdale Donald, English Shane W
Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, Sydney, Australia.
Critical Care Program, The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
Transl Stroke Res. 2025 Feb;16(1):49-78. doi: 10.1007/s12975-024-01271-8. Epub 2024 Jul 13.
Aneurysmal subarachnoid haemorrhage (aSAH) is a devastating condition with high mortality and morbidity. The outcome measures used in aSAH clinical research vary making it challenging to compare and combine different studies. Additionally, there may be a mismatch between the outcomes prioritized by patients, caregivers, and health care providers and those selected by researchers. We conducted an international, online, multiple round Delphi study to develop consensus on domains (where a domain is a health concept or aspect) prioritized by key stakeholders including those with lived experience of aSAH, health care providers, and researchers, funders, or industry professionals. One hundred seventy-five people participated in the survey, 59% of whom had lived experience of aSAH. Over three rounds, 32 domains reached the consensus threshold pre-defined as 70% of participants rating the domain as being critically important. During the fourth round, participants ranked the importance of each of these 32 domains. The top ten domains ranked highest to lowest were (1) Cognition and executive function, (2) Aneurysm obliteration, (3) Cerebral infarction, (4) Functional outcomes including ability to walk, (5) Delayed cerebral ischemia, (6) The overall quality of life as reported by the SAH survivor, (7) Changes to emotions or mood (including depression), (8) The basic activities of daily living, (9) Vasospasm, and (10) ICU complications. Our findings confirm that there is a mismatch between domains prioritized by stakeholders and outcomes used in clinical research. Our future work aims to address this mismatch through the development of a core outcome set in aSAH research.
动脉瘤性蛛网膜下腔出血(aSAH)是一种具有高死亡率和高发病率的灾难性疾病。aSAH临床研究中使用的结局指标各不相同,这使得比较和整合不同研究具有挑战性。此外,患者、护理人员和医疗保健提供者所优先考虑的结局与研究人员所选择的结局之间可能存在不一致。我们开展了一项国际在线多轮德尔菲研究,以就关键利益相关者(包括有aSAH亲身经历者、医疗保健提供者以及研究人员、资助者或行业专业人士)所优先考虑的领域(其中一个领域是一个健康概念或方面)达成共识。175人参与了该调查,其中59%有aSAH亲身经历。经过三轮调查,32个领域达到了预先定义的共识阈值,即70%的参与者将该领域评为至关重要。在第四轮调查中,参与者对这32个领域的重要性进行了排序。从最高到最低排名前十的领域分别是:(1)认知和执行功能,(2)动脉瘤闭塞,(3)脑梗死,(4)包括行走能力在内的功能结局,(5)迟发性脑缺血,(6)SAH幸存者报告的总体生活质量,(7)情绪或心境变化(包括抑郁),(8)日常生活基本活动,(9)血管痉挛,以及(10)重症监护病房并发症。我们的研究结果证实,利益相关者所优先考虑的领域与临床研究中使用的结局之间存在不一致。我们未来的工作旨在通过制定aSAH研究的核心结局集来解决这种不一致。